Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7919427rdf:typepubmed:Citationlld:pubmed
pubmed-article:7919427lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:7919427lifeskim:mentionsumls-concept:C0015982lld:lifeskim
pubmed-article:7919427lifeskim:mentionsumls-concept:C0242485lld:lifeskim
pubmed-article:7919427lifeskim:mentionsumls-concept:C0699900lld:lifeskim
pubmed-article:7919427lifeskim:mentionsumls-concept:C0243125lld:lifeskim
pubmed-article:7919427lifeskim:mentionsumls-concept:C1522492lld:lifeskim
pubmed-article:7919427lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:7919427pubmed:issue2lld:pubmed
pubmed-article:7919427pubmed:dateCreated1994-10-27lld:pubmed
pubmed-article:7919427pubmed:abstractTextIntraglomerular fibrin deposition has been implicated as an important pathogenetic mechanism in patients with glomerular diseases and the nephrotic syndrome. To investigate fibrin formation and degradation in nephrosis, we measured fibrinopeptide A by radioimmunoassay and D-dimer by enzyme-linked immunosorbent assay in the plasma of 30 consecutive adult patients with the nephrotic syndrome; in 10 the serum creatinine was more than 2 mg/dl. Both fibrinopeptide A and D-dimer were abnormally elevated in the majority of nephrotics (P < 0.001 vs. healthy controls), providing evidence of increased fibrin generation and lysis "in vivo." A positive correlation was found between fibrinopeptide A and D-dimer (correlation coefficient 0.64, P < 0.001), suggesting a close relationship between fibrin formation and degradation. Calcium heparin, administered to 12 nephrotics, caused a marked decrease in plasma fibrinopeptide A, due to a reduction of in vivo thrombin activity. As enhanced thrombin activity can favor fibrin deposition within the renal parenchyma, as well as vascular complications, it is reasonable to assume that an antithrombotic treatment aimed at controlling thrombin generation may ameliorate the natural history of nephrosis.lld:pubmed
pubmed-article:7919427pubmed:languageenglld:pubmed
pubmed-article:7919427pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7919427pubmed:citationSubsetIMlld:pubmed
pubmed-article:7919427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7919427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7919427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7919427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7919427pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7919427pubmed:statusMEDLINElld:pubmed
pubmed-article:7919427pubmed:issn0940-5437lld:pubmed
pubmed-article:7919427pubmed:authorpubmed-author:BaicchiUUlld:pubmed
pubmed-article:7919427pubmed:authorpubmed-author:SagripantiAAlld:pubmed
pubmed-article:7919427pubmed:authorpubmed-author:FerdeghiniMMlld:pubmed
pubmed-article:7919427pubmed:authorpubmed-author:BarsottiGGlld:pubmed
pubmed-article:7919427pubmed:authorpubmed-author:CupistiAAlld:pubmed
pubmed-article:7919427pubmed:issnTypePrintlld:pubmed
pubmed-article:7919427pubmed:volume24lld:pubmed
pubmed-article:7919427pubmed:ownerNLMlld:pubmed
pubmed-article:7919427pubmed:authorsCompleteYlld:pubmed
pubmed-article:7919427pubmed:pagination113-6lld:pubmed
pubmed-article:7919427pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:meshHeadingpubmed-meshheading:7919427-...lld:pubmed
pubmed-article:7919427pubmed:year1994lld:pubmed
pubmed-article:7919427pubmed:articleTitleIn vivo measurements of fibrin formation and degradation in nephrotic patients.lld:pubmed
pubmed-article:7919427pubmed:affiliation1st Clinical Medicine Institute, University Hospital, Pisa, Italy.lld:pubmed
pubmed-article:7919427pubmed:publicationTypeJournal Articlelld:pubmed